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Abstract
Background: We update a previous systematic review to inform new World Health Organization HIV self-testing
(HIVST) recommendations. We compared the effects of HIVST to standard HIV testing services to understand which
service delivery models are effective for key populations.
Methods: We did a systematic review of randomised controlled trials (RCTs) which compared HIVST to standard
HIV testing in key populations, published from 1 January 2006 to 4 June 2019 in PubMed, Embase, Global Index
Medicus, Social Policy and Practice, PsycINFO, Health Management Information Consortium, EBSCO CINAHL Plus,
Cochrane Library and Web of Science. We extracted study characteristic and outcome data and conducted risk of
bias assessments using the Cochrane ROB tool version 1. Random effects meta-analyses were conducted, and
pooled effect estimates were assessed along with other evidence characteristics to determine the overall strength
of the evidence using GRADE methodology.
Results: After screening 5909 titles and abstracts, we identified 10 RCTs which reported on testing outcomes. These
included 9679 participants, of whom 5486 were men who have sex with men (MSM), 72 were trans people and
4121 were female sex workers. Service delivery models included facility-based, online/mail and peer distribution.
Support components were highly diverse and ranged from helplines to training and supervision. HIVST increased
testing uptake by 1.45 times (RR=1.45 95% CI 1.20, 1.75). For MSM and small numbers of trans people, HIVST
increased the mean number of HIV tests by 2.56 over follow-up (mean difference = 2.56; 95% CI 1.24, 3.88). There
was no difference between HIVST and SoC in regard to positivity among tested overall (RR = 0.91; 95% CI 0.73, 1.15);
in sensitivity analysis of positivity among randomised HIVST identified significantly more HIV infections among MSM
and trans people (RR = 2.21; 95% CI 1.20, 4.08) and in online/mail distribution systems (RR = 2.21; 95% CI 1.14, 4.32).
Yield of positive results in FSW was not significantly different between HIVST and SoC. HIVST reduced linkage to
care by 17% compared to SoC overall (RR = 0.83; 95% CI 0.74, 0.92). Impacts on STI testing were mixed; two RCTs
showed no decreases in STI testing while one showed significantly lower STI testing in the intervention arm. There
were no negative impacts on condom use (RR = 0.95; 95% CI 0.83, 1.08), and social harm was very rare.
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Conclusions: HIVST is safe and increases testing uptake and frequency as well as yield of positive results for MSM
and trans people without negative effects on linkage to HIV care, STI testing, condom use or social harm. Testing
uptake was increased for FSW, yield of positive results were not and linkage to HIV care was worse. Strategies to
improve linkage to care outcomes for both groups are crucial for effective roll-out.
Keywords: HIV self-testing, Men who have sex with men, Trans people, Female sex workers, Meta-analysis, HIV
prevention, HIV testing
Background
There has been significant progress and scale-up of HIV
testing services in the past decade. In 2018, it was esti-
mated that globally 79% of people with HIV were aware
of their status, the majority of whom were on treatment
and achieving viral suppression [1]. Despite this
progress, more than 5 million people with HIV remain
undiagnosed [1].
Undiagnosed and untreated HIV infections contribute
to the majority of new infections. Studies in the USA
and UK suggest that between 60 and 80% of new infec-
tions were transmitted by people who did not know
their status, or who were not yet on treatment [2, 3].
Key populations are disproportionately impacted by
HIV despite making up small proportions of the overall
population. Approximately 54% of all new infections
were among key populations (men who have sex with
men (MSM), people who inject drugs (PWID), people in
prisons and other closed settings, sex workers and trans
people) and their partners in 2018. Increasing HIV test-
ing, prevention and treatment coverage, along with viral
suppression, among these groups is a global health
priority.
HIV self-testing (HIVST), whereby a person collects
their own sample, performs a rapid test and then inter-
prets their own result, has been highlighted as an import-
ant approach for reaching key populations [4–7].
Because of its convenient and private nature, HIVST in-
terventions have the potential to increase uptake and
frequency of testing among those less likely to test
through other mechanisms by overcoming structural
and individual barriers including direct and opportunity
costs, as well as fear of stigma and discrimination [6, 8–
12]. By reaching those less likely to test, HIVST may
lead to the detection of greater numbers of previously
undiagnosed infections when compared to standard
approaches.
While there has been longstanding interest in HIVST,
implementation is relatively new. Following the comple-
tion of five randomised controlled trials (RCTs) in
addition to large-scale country evaluations, in 2016, the
World Health Organization (WHO) recommended HIVS
T as an additional testing approach [13]. This guidance
was based on evidence showing that HIVST was a safe
and effective way to increase testing uptake and
frequency.
As of June 2019, 77 countries had supportive policies,
but HIVST had only been implemented in 38 [14]. To
facilitate scale-up of HIVST, it is essential to understand
which service delivery approaches are the most safe,
acceptable and effective for reaching different key
populations.
This review aims to compare the effects of HIVST to
standard HIV testing and to understand which HIVST
service delivery models are effective for key populations.
It was conducted to update the WHO guidelines and
recommendations on HIVST. In doing so, we updated a
previous systematic review and meta-analysis, in order
to capture significant development in the evidence base
since that prior review [15]. This is one among a series
of reviews examining outcomes for general populations,
key populations and intervention values and preferences
of HIVST users as well as a network meta-analysis.
Methods
This systematic review was conducted in line with the
PRISMA guidelines for systematic reviews and meta-
analyses [16].
Searches, screening and data extraction
Our review followed a PICO question (see Table 1)
which was determined as part of the 2019 WHO HIVST
guidelines development process [17, 18]. We limited eli-
gibility to RCTs reporting on one of more of our out-
comes among at least one key population and which
sought to compare HIVST against any other HIV testing
intervention, referred to as standard of care (SoC) [19].
We had no limits on language but only included litera-
ture published in academic journals and conferences.
The full review protocol, including search details, is
available in Additional file 1.
The search strategy was previously validated for
systematic mapping of HIVST literature [18]. Databases
searched include PubMed, Embase, Global Index
Medicus, Social Policy and Practice, PsycINFO, Health
Management Information Consortium, EBSCO CINAHL
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Plus, Cochrane Library and Web of Science [18]. These
were first searched from 1 January 2006 to 1 January
2016 and then updated monthly until 4 June 2019. Con-
ference abstract searches included African Society for
Laboratory Medicine Conference (ASLM), Conference
on Retroviruses and Opportunistic Infections (CROI),
International AIDS Conference and International AIDS
Society Conference (IAS). For CROI, only the most re-
cent conferences (2014–2019) were searched as past
conferences are inaccessible. We also searched AIDS
Impact 2019.
Titles and abstracts were reviewed in duplicate by the
first author and other members of the study team (CF,
DR, NT, MSJ). These were then screened by two re-
searchers (TCW and MSJ) for inclusion. Authors of one
study (MacGowan et al. [20]) were aware of this meta-
analysis following requests for additional data from an
earlier conference presentation. They alerted us to the
published manuscript with updated analyses, which we
included for completeness.
Outcome data were extracted in duplicate by two re-
searchers (TCW and one of NT, MSJ, IE-W) using stan-
dardised extraction forms and entered into a relational
database tool (airtable.com). Disagreements were
resolved by consensus. Where data were not available,
authors were contacted for additional information.
The outcomes included (1) uptake of HIV testing, (2)
frequency of HIV testing (mean number of tests over a
period of time), (3) HIV positivity (positive results/all
tested and positive results/all randomised), (4) linkage to
treatment or care, (5) uptake and frequency of sexually
transmitted infections (STI) testing, (6) condom use and
(7) social harm or adverse events. Linkage was a binary
variable with any linkage to care or ART initiation as re-
ported by authors. For positivity, we conducted an ana-
lysis of test positivity (proportion of positive results
among those tested) and a sensitivity analysis using the
number of participants randomised as denominator
(intention-to-treat approach). All studies including trans
people grouped this population with MSM; we therefore
report these two groups as one.
Quality assessment
The Cochrane risk of bias tool was used to evaluate
studies for methodological quality [21]. This included
evaluation of risk of bias pertaining to random sequence
generation, allocation concealment, blinding of
participants and personnel, attrition bias and reporting
bias [21]. Publication bias was assessed with forest plots
when there were sufficient studies to do so (n > 10).
We followed GRADE methodology to assess the cer-
tainty of the evidence for each outcome across GRADE
domains: methodological quality, imprecision, indirect-
ness, inconsistency and publication bias [17, 19]. Hetero-
geneity was defined as either low (i2 < 25%), medium
(i2 = 25–75%) or high (i2 > 75%).
Data analysis
Where more than two studies reported the same or a
comparable outcome, a meta-analysis was conducted.
All meta-analyses were conducted using random effects
models (inverse-variance method) in RevMan 5.4. For
dichotomous outcomes, risk ratios (RRs) and 95% confi-
dence intervals (CIs) were calculated and pooled. For
continuous outcomes, mean differences with 95% CIs
were calculated and pooled. Statistical heterogeneity was
evaluated using the DerSimonian-Laird estimator for
Tau2 and the associated I2 statistic. For each outcome
within the meta-analysis, we generated forest plots over-
all and by each stratification. Where possible, we per-
formed sub-group analyses on key population group
(MSM and trans people; FSW) and by service delivery
model (facility-based; online/mail; peer distribution).
When outcomes were measured and reported at mul-
tiple timepoints, we used the longest timepoint where
possible. For two studies, we used the earliest timepoints
for both uptake and positivity because uptake data were
not cumulatively reported from multiple timepoints
whereas positivity data were, prohibiting comparison at
later timepoints.
For cluster RCTs, we included cluster-adjusted RRs
and CIs as reported by the authors where possible.
For RCTs with multiple intervention arms (1) data
from different intervention arms were combined where
reviewers assessed the interventions as unlikely to influ-
ence the outcome, and (2) where reviewers assessed the
interventions as likely to influence the outcome, the
intervention arms were not combined for delivery model
sub-group analyses. Where one of the intervention arms
was an enhanced or optimised version of control arm,
we did not include it in meta-analysis.
We did not perform sub-group analyses by support
tools (e.g. online counselling; enhanced instructions)
Table 1 Review PICO
Population Key populations receiving HIV testing services
Intervention Interventions which provide HIVST
Comparison HIV testing interventions which do not use HIVST
Outcomes HIV testing uptake, HIV testing frequency, STI testing frequency, condom use, HIV positivity, linkage to care, adverse events
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used in the RCTs as they were highly heterogenous with
very small numbers in each category.
This systematic review was not registered as it was
part of an internal endeavour commissioned by the
WHO to update their normative HIVST guidance.
Results
We identified 14,254 records from databases, 77 confer-
ence abstracts and 3 from other sources. After duplicates
were removed, 5909 titles and abstracts were screened
for eligibility. We screened 627 full-text articles for eligi-
bility. Eleven studies reporting results from 10 RCTs
met inclusion criteria. See Fig. 1 for full PRISMA dia-
gram and Additional file 2 for risk of bias assessments.
The ten RCTs enrolled 9679 participants of whom
5486 were MSM, 72 were trans people (mostly trans
women) and 4121 were FSW. No trials among people
who inject drugs or people in prisons or closed settings
were identified. Table 2 provides summaries of included
studies and details of support tools used in the RCTs.
All studies included only participants with negative or
unknown HIV status.
Most of the seven studies including MSM were con-
ducted in high-income settings (four in the USA [20, 24,
26, 31], one in Australia [23], one in Hong Kong [30]),
except for one RCT in China (a medium high-income
setting) [29]. All studies including FSW were conducted
in low or lower middle-income settings, all in sub-
Saharan Africa (one each in Kenya [25], Uganda [27, 28]
and Zambia [22]). All studies used oral fluid-based HIVST
kits, except one which provided oral fluid and also finger-
prick/blood-based HIVST [20]. All studies provided kits
free of charge. Jamil et al. [23], MacGowan et al. [20] and
Katz et al. [24] enabled individuals to take more than one
kit per person at a time and to collect additional HIVST
kits during the study period. Ortblad et al. and Chanda
et al. provided a second HIVST in intervention arms at 3
months [22, 27].
The 10 RCTs included 13 HIVST interventions. All
compared HIVST against SoC. A range of intervention
designs were identified. Most interventions delivered
Fig. 1 Flowchart of the selection of studies
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Table 2 Characteristics of included RCTs
Study Country Total
randomised





Zambia 965 FSW • Peer educator provided risk reduction
counselling; condom distribution; HIV
testing information
• Group HIVST demonstration
• Peer educator delivered HIVST kit (arm
1)
• Peer educator delivered coupons for
HIVST collection at facilities (arm 2)












Australia 362 MSM • 4 HIVST kits at enrolment, option to
request additional kits (max 12 per
year)
• 24/7 telephone hotline









USA 230 MSM (n=226), trans
people (n=4; 1 trans
woman, 3 gender-
queer/neutral)
• 1 HIVST kit at enrolment, option to
request additional kits (max 1 per
month)
• In-person demonstration; information
about HIV testing and reminders; 24/7
telephone hotline
• HIV testing advice
• Offer of testing reminders









Kenya 2196 FSW • Choice of supervised self-administered
HIVST at facility (overseen by health
worker) or free HIVST kit for home use
• Provider administered
testing





USA 2665 MSM • 4 HIVST kits at enrolment (mail), option
to request additional kits 3 monthly
• HIV testing information; 24/7 telephone
hotline






USA 425 MSM (18–24 years) • Internet gift card for online order of
HIVST kit
• HIV testing advice







Uganda 960 FSW • Peer educator provided risk reduction
counselling; condom distribution; HIV
testing information
• Group HIVST demonstration
• Peer educator delivered HIVST kit (arm
1)
• Peer educator delivered coupons for
HIVST collection at facilities (arm 2)












China 1381 MSM (n=1313), trans
women (n=68)
• Access to HIVST kits promoted via
social media along with a promotional
campaign on HIV testing









430 MSM • 1 HIVST kit at enrolment (mail)
• 3 min online video promoting HIV
testing; 4 min online video promoting
HIVST; 15 min motivational interview
conducted over the phone by trained
staff to promote HIVST
• Real-time instructions and pre/post-test
counselling provided online
• Accompaniment to clinic appointment
for confirmatory testing






USA 65 MSM • HIVST kits mailed at 3 monthly intervals
(arm 1)
• HIVST kits fitted with Bluetooth device
mailed at 3 monthly intervals (arm 2)
• Follow-up by counsellor when kit
opened; risk reduction counselling and
referral to prevention services (arm 2)
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HIVSTs through facilities (n= 5) [22–25, 27] or online/mail
distribution systems (n= 6) [20, 26, 29–31], with a minority
(n= 2) delivering kits through peers [22, 27]. Both trials dis-
tributing through peers targeted FSW only [22, 27].
Support tools were highly diverse. Two interventions
delivered to MSM included real-time pre- and post-test
counselling, one through a prearranged video appoint-
ment system [30] and one through a Bluetooth beacon
which activated when the kit was opened prompting a
counsellor to contact the user [31]. Three MSM studies
offered telephone hotlines [20, 23, 24]. The provision of
risk reduction information was included in three studies
[22, 27, 31].
Additional file 3 presents a summary of findings in-
cluding GRADE assessments.
Uptake of HIV testing
All ten RCTs reported on uptake of HIV testing across
12 HIVST interventions1 [20, 22–27, 29–31]. A meta-
analysis showed that HIVST increased the uptake of
HIV testing by 1.45 times compared to SoC (relative risk
(RR) = 1.45; 95% CI 1.20, 1.75; I2 = 97%; moderate-
quality evidence). Eight of the 10 RCTs showed a
statistically significant increase in uptake of HIV testing.
Publication bias was assessed for this outcome, funnel
plots showed benefit from all studies and we assessed
this was true intervention impact (see Additional file 4).
Seven of the ten RCTs included data for MSM; two of
these also included trans people [20, 23, 24, 26, 29–31]. A
sub-group analysis of these showed that HIVST increased
the uptake of HIV testing by 1.48 times compared to SoC
(RR = 1.48; 95% CI 1.21, 1.81; I2 = 95%; low-quality
evidence).
Three RCTs were conducted among FSW [22, 25, 27].
Our sub-group analysis indicated HIVST increased up-
take of testing (RR = 1.36; 95% CI 1.04, 1.78; I2 = 95%;
moderate-quality evidence) (see Additional file 5).
A sub-group analysis of five interventions delivering
HIVST to MSM, trans people and FSW through facilities
showed HIVST increased uptake by 1.28 times (RR =
1.28; 95% CI 1.00, 1.64; I2 = 95%; moderate-quality evi-
dence) [22–25, 27]. Secondary distribution through peers
among FSW showed HIVST increased uptake by 1.12
times (RR = 1.12; 95% CI 1.05, 1.20; I2 = 31%; moderate-
quality evidence) [22, 27]. Sub-group analysis of online/
mail distribution in MSM and trans people found that
HIVST delivered this way increased uptake by 1.61 times
(RR = 1.61; 95% CI 1.33, 1.94; I2 = 92%; moderate-quality
evidence) [20, 26, 29–31]. Figure 2 provides delivery
method stratification meta-analysis results.
Frequency of HIV testing
A meta-analysis of three RCTs found that HIVST in-
creased mean number of HIV tests by 2.56 during
follow-up (mean difference = 2.56; 95% CI 1.24, 3.88;
I2 = 99%; moderate-quality evidence) (Fig. 3); all RCTs
showed benefit [20, 23, 24]. Two studies delivered HIVST
through facility distribution (with additional, optional mail
distribution) and had smaller effect sizes at 2.1 and 1.7, re-
spectively [23, 24]. One delivered HIVST through mail
and demonstrated the largest difference at 3.80 [20]. All
studies were conducted with MSM with small numbers of
trans people also included in one.
HIV positivity
Nine of the 10 RCTs reported on positive results among
tested. A meta-analysis indicated HIVST had no effect
on HIV positivity among those tested (IRR = 0.91; 95%
CI 0.73, 1.15; I2 = 4%; low-quality evidence) [20, 22–27,
30, 31]. No sub-group analyses among population
groups showed significant differences (Fig. 4).
A sub-group analysis of delivery mechanisms showed
no significant differences in HIV positivity among those
tested in online/mail distribution (RR = 1.41; 95% CI
0.73, 2.75; I2 = 0%; moderate-quality evidence), in
facility-based distribution (RR = 0.99, 95% CI 0.59, 1.66;
I2 = 38%; moderate-quality evidence) or in secondary
HIVST distribution through peers (RR = 0.78; 95% CI
0.57, 1.06; I2 =0; low-quality evidence) (forest plot avail-
able in Additional file 5).
Sensitivity analysis of positivity by total number ran-
domised provided different results. Overall differences
between HIVST and SoC were not significant. How-
ever, in a sub-group analysis of seven studies conducted
among MSM (one including trans people) [20, 23, 24,
26, 30, 31], HIVST arms yielded more than double the
rate of positivity compared to SoC arms (RR = 2.21;
95% CI 1.20, 4.08; I2 = 0%; moderate-quality evidence).
Significant differences were not seen for FSW (Fig. 5)
[22, 25, 27].
In sub-group analyses, online/mail distributed HIVS
T found increased the rate of positivity among all ran-
domised by 2.21 times compared to SoC (RR = 2.21;
95% CI 1.14, 4.32; I2 = 0%; moderate-quality evi-
dence). No significant differences were observed in
peer or facility-based delivery of HIVST compared to
SoC (see Additional file 5 for forest plot).
Linkage to care
Six RCTs measured linkage to HIV care or antiretroviral
therapy among key populations diagnosed with HIV [20,
22–24, 27, 30]. A meta-analysis of moderate-quality evi-
dence indicated that HIVST reduced linkage to care by
17% (RR = 0.83; 95% CI 0.74, 0.92; I2 = 0%; moderate-
quality evidence). In population sub-group analyses,
1Two interventions reported in Wray et al. [31] were combined for
this analysis as differences between them were assessed as unlikely to
affect this outcome.
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HIVST reduced linkage in FSW by 16% (RR = 0.84; 95%
CI 0.75, 0.94; I2 = 19%). Results were not significant in
sub-group analysis for MSM and trans people (see Fig. 6).
One study provided linkage support in the form of
online counselling [30], three provided a 24-h helpline
[20, 23, 24] and a further two provided enhanced written
information with kits [22, 27].
Uptake and frequency of STI testing
Results related to STI testing behaviour varied. Three
studies reported on this, all including MSM and one also
including trans people [23, 24, 31]. One study measuring
STI testing across three interventions (HIVST only,
HIVST with counselling, SoC) found no differences
across the three interventions [31]. A study in Australia
found no differences in STI testing frequency in HIVST
and SoC arms (RR = 0.92; 95% CI 0.80, 1.07) [23].
Another study in the USA delivering HIVST through
facilities and mail found MSM and trans people in the
HIVST arm reported significantly fewer STI tests than
those in the SoC arm (HIVST arm mean = 2.3; 95% CI 1.9,
2.7; SoC arm mean = 3.2; 95% CI 2.8, 3.6; p = 0.0038) [24].
The first two of these studies involved facility-based distri-
bution while the latter provided HIVST through online/
mail distribution. A meta-analysis was not conducted due
to heterogeneity of outcomes.
Condom use
A meta-analysis of five trials found that among MSM
and FSW, HIVST had no statistically significant effect
on condomless sex (RR = 0.95; 95% CI 0.83, 1.08; i2 =
52%; low-quality evidence) (see Fig. 7) [23, 24, 28–30]. A
further study found some evidence of difference on this
outcome between HIVST interventions with and without
counselling and SoC [31]. This study comparing HIVST
without counselling, HIVST with counselling and SoC
found that significantly fewer MSM in the HIVST and
counselling arm reported CAI compared with both other
interventions (IRR = 0.20, SE = 0.09, p < 0.001) [31]. A
study of online/mail distribution found no difference in
Fig. 2 Meta-analysis of studies evaluating HIV testing uptake with delivery mechanism stratification
Fig. 3 Meta-analysis of studies evaluating HIV testing frequency
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CAI partners between intervention (mean = 1.63; SD =
3.45) and SoC (mean = 1.41; SD = 2.51) arms at
12 months (p = 0.17) [20]. These results could not be in-
cluded in the meta-analysis as they were both conti-
nuous rather than binary variables.
Social harm or adverse events
Social harm or other adverse events were reported sys-
tematically in two RCTs among FSW, one in Uganda
and one in Zambia [22, 27]. One study showed four inci-
dents of intimate partner violence (IPV) in an HIVST
arm and none in the SoC arm. Three of these events
were following a partner learning of HIVST use, while
the fourth was following a partner learning about en-
gagement in sex work [22]. The other study reported
two incidents of IPV in the HIVST arms and one in the
SoC arm. In the HIVST arm, one person suffered verbal
abuse from a boyfriend following self-testing, and the
other two events were related to sex work disclosure
[27]. Mental distress was reported following a positive
HIVST result [27]. Neither study showed statistically
significant differences across arms.
Discussion
This systematic review and meta-analysis of 10 RCTs
conducted with key populations found that distribution
of free HIVST kits increases the uptake of HIV testing
when compared to SoC among key populations overall
and in all sub-group analyses.
HIVST increased the frequency of testing in MSM and
trans people. Effect sizes for this measure were strongest
in the study using an online ordering for mail
Fig. 4 Meta-analysis of studies evaluating HIV positivity among tested with population stratification
Fig. 5 Meta-analysis of studies evaluating HIV positivity among randomised with population stratification
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distribution model. Although it did not meet our testing
frequency outcome definition, and therefore was not in-
cluded in our analysis, one study demonstrated that
HIVST could increase the proportion of FSW who
tested twice in 4 months [27].
Nine of 10 RCTs included in this review assessed the
impact of HIVST on HIV positivity, with significant dif-
ferences observed. Results for MSM and trans people
were not significantly different among those tested, but
in those randomised HIVST doubled the rate of positiv-
ity compared to SoC. Results were not significant for
FSW in either analysis. This was also reflected in online/
mail distribution with more infections detected in HIVST
arms, while no other models showed difference. This in-
dicates that for MSM and trans people, HIVST has the
potential to increase overall yield of positive results but
does not increase test positivity compared to standard
approaches. This increase in overall number of infec-
tions detected is likely because greater numbers of
MSM and trans people test when presented with HIVST
compared to SoC (as demonstrated in uptake analysis)
due to self-testing reducing well-documented barriers
such as stigma, confidentiality concerns and issues of
convenience. Online/mail delivered HIVST may have
benefits over other models for similar reasons.
HIVST approaches performed less well than SoC in
linking those with positive results to care overall and
among FSW. Results for MSM and trans people were not
statistically significantly different. It is important to note
that RCTs may have been underpowered to assess these
outcomes given the large number of HIV positive diagno-
ses required to demonstrate differences. A further issue is
that many of these trials relied upon self-report for HIV
positivity and linkage to care, and it may be especially
challenging to confirm numbers of new positive results in
an intervention which is by its nature dislocated from clin-
ical services and potentially utilised by those with the most
pronounced barriers to access. Nevertheless, careful con-
sideration to this issue is required in HIVST implementa-
tion, especially in groups least likely to engage in care.
Evidence on the frequency of STI screening for MSM
(and small numbers of trans people in one study) was
mixed; two studies showed no negative effect, but one
study found a significant reduction in STI testing fre-
quency. Concerns regarding reduced STI testing with
HIVST may be alleviated by providing STI self-sample
testing alongside HIVST where feasible, and using a
strategic approach to implement HIVST for those most
likely to have unmet HIV testing need and/or undiag-
nosed HIV.
Fig. 6 Meta-analysis of studies evaluating linkage to care with population stratification
Fig. 7 Meta-analysis of studies evaluating condomless sex among FSW, MSM and trans people
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HIVST appears to be a safe and acceptable interven-
tion among key populations. Encouragingly, HIVST had
no negative impacts on condom use, results which coun-
ter a key concern frequently raised [6, 7, 32]. There were
no serious adverse events reported by RCTs, and social
harms were extremely rare, again countering common
concerns [6, 7, 32, 33]. Future research on, and im-
plementation of, HIVST for key populations should
remain attentive to issues of potential harm. This is
critical where individuals live in an environment of
power inequalities and higher rates of background
violence, salient issues for FSW, MSM and trans
people [22, 27, 33, 34].
These results indicate that HIVST can be a useful ap-
proach to increase the uptake of HIV testing among
MSM and FSW, with evidence of increases in testing fre-
quency primarily available for MSM. Online ordering for
mail delivery appears to have benefits over facility-based
and peer distribution models, potentially because mecha-
nisms were perceived to be more private. These differ-
ences may be due to the values and preferences of these
populations regarding maximally convenient HIVST
approaches requiring minimal healthcare provider inter-
action [6, 11, 35]. It is worth reiterating that peer/sec-
ondary distribution evidence in this review is only drawn
from FSW populations, and the approach may also be
useful with other populations, especially MSM and trans
people. In MacGowan et al. [20], an additional person
with HIV was identified through kit sharing, and this
distribution approach has been used successfully in pilot
and demonstration project with MSM and with trans
FSW [20, 34, 36, 37]. Careful intervention design should
be attentive to local contexts and the specific needs of
key populations, ensuring that interventions are accept-
able and accessible.
Given high acceptability [6–10, 35, 38] and effective-
ness, HIVST should be implemented more widely and
scaled-up among MSM. For FSW populations, although
HIVST does increase testing uptake, additional caution
is warranted regarding implementation because of nega-
tive impacts on linkage to care. Indeed, innovative ap-
proaches to facilitating linkage for all populations are
important to optimise interventions and ensure that
individuals are not lost to care.
It should be noted that heterogeneity for some out-
comes was high. This is perhaps due to the inclusion of
a broad range of evidence from multiple settings deliver-
ing HIVST to various populations through a multitude
of intervention types. This underlines the importance of
developing interventions based on the needs of the set-
ting and the target populations.
Although our uptake funnel plot showed that overall
there were few small studies all which showed benefit, we
assessed this is not the result of publication bias but rather
related to the inclusion of RCTs only in our review, which
by their nature require sufficient numbers of patients to
show effects. We assessed this as the true effect of HIVST
on uptake of HIV testing, as these results mirror findings
from general populations in several settings and observa-
tional studies with key populations [38–41].
Evidence gaps
It is unlikely that many additional large-scale RCTs will
be implemented. Nevertheless, some significant gaps
exist in the evidence which implementation, pilot and
demonstration projects can respond to.
Firstly, there was extremely limited data from trans
populations, with only 72 of 9679 participants identify-
ing as trans, no study which separated trans women
from trans men and no RCT reporting outcomes for this
group independently of MSM. This is a population with
pronounced testing need, which observational evidence
suggests HIVST may meet [8, 34].
Secondly, no RCT evidence was found for PWID or
people in prisons, two groups which may also find HIVST
acceptable. For people in prisons, ways to ensure confi-
dentially and prevent coercion are critical—as they are for
any testing approach in closed settings. It is also possible
that these approaches will not be acceptable to staff
working in these settings because of device-related safety
concerns.
Finally, some outcomes of interest were not recorded
in specific population groups. Adverse events were not
reported in RCTs recruiting MSM and trans people (al-
though numerous studies have shown that HIVST is
highly acceptable for this group [10, 11, 35, 40, 42–46]).
Condom use outcomes were collected mainly in RCTs
among MSM, with only one RCT reporting on inconsist-
ent condom use for FSW [28]. Frequency of HIV testing
was only examined among MSM and a small number of
trans people. Generating this evidence base and develop-
ing delivery approaches for all populations through
implementation research are a critical priority.
Strengths and limitations
This systematic review and meta-analysis has some key
strengths and some important limitations. Overall, the
evidence identified was of low-to-moderate quality.
Many included studies relied on self-reported outcomes,
including for testing uptake and positivity, which need
to be taken into account when assessing evidence
quality.
This is the first systematic review and meta-analysis
comparing HIVST to SoC conducted exclusively using
data from key populations. Our comprehensive search
strategy and systematic review process is a significant
strength, as is our assessment of risk of bias and inde-
pendent data extraction process. Since the first meta-
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analysis comparing HIVST to SoC (see Johnson et al.
[15]), several studies have reported which strengthen the
findings, especially around uptake and frequency of test-
ing, HIV positivity and condom use.
Our systematic approach has enabled the identification
of a broad range of evidence covering MSM and FSW,
with some for trans people. Further experience and evi-
dence of HIVST for trans men and women should be
prioritised as trans populations often face serious bar-
riers to service access.
At the time of the review, there was insufficient and
heterogenous evidence on differences in support tools
with HIVST. When this evidence base develops further,
evaluating the impact of support tools may provide add-
itional insights into the utility of a range of supportive
options which can optimise outcomes.
The vast majority of interventions in this systematic
review used oral fluid HIVSTs. These have benefits in
terms of ease of use but drawbacks regarding lower test
sensitivity, particularly in early infection [7, 47]. Al-
though HIVST interventions comprise multiple compo-
nents in addition to the kit itself (see Table 2), this
evidence base should not be considered representative of
blood-based HIVSTs which require the user to collect a
blood sample which is a barrier for some [6, 7, 11]. In
addition, blood-based HIVSTs have improved sensitivity
and may therefore identify larger numbers of HIV infec-
tions among those tested [7, 47].
A further limitation is drawn from the GRADE meth-
odology. Allocation blinding is a central feature of risk
of bias assessments within the GRADE system. Interven-
tions like HIVST cannot be blinded, and all outcomes
are therefore downgraded one position. Using this meth-
odology which was designed with double blind trials in
mind may artificially reduce our confidence in the inter-
vention and its associated outcomes.
Conclusions
In this review, HIVST, in RCTs, was found to be safe,
and increased testing uptake, frequency and overall posi-
tivity rate for MSM and trans people when compared to
standard HIV testing services, without negative effects
on condom use or substantial increases in social harm.
HIVST did not improve linkage to care compared to
SoC in MSM and trans people. Results for female sex
workers were more mixed: although testing uptake was
improved, yield of positive results (test positivity or
among randomised) was not and linkage outcomes were
worse. Across key populations, more evidence is re-
quired to assess impact on STI testing frequency. This
review highlights the importance of developing strategies
to ensure linkage which meet the needs of intended
beneficiaries in a variety of settings.
Among key populations, HIVST appears to engage
segments of the population with pronounced barriers to
standard testing services while increasing choice. HIVST
therefore has an important role within broader HIV pre-
vention efforts improving uptake of HIV testing services;
it is crucial that interventions are designed in response
to local need.
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